

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: SUBOXONE (BUPRENORPHINE
HYDROCHLORIDE AND NALAXONE)
ANTITRUST LITIGATION** : **MDL NO. 2445**
: **13-MD-2445**
:
:
:

THIS DOCUMENT APPLIES TO: :

*Amneal Pharmaceuticals LLC v.
Indivior Inc. et al., 16-cv-563* :
:
:
:
:

ORDER

AND NOW, this 4th day of January, 2017, upon consideration of “Indivior, Inc.’s Partial Motion to Dismiss Amneal’s Complaint” (Doc. No. 10), the response, reply and sur-reply thereto, following oral argument, and in accordance with accompanying Memorandum Opinion, it is hereby **ORDERED** that Indivior’s motion to dismiss is **GRANTED** in part and **DENIED** in part as follows:

- Amneal’s standalone delay claim relating to the REMS/SSRS process is **DISMISSED**.
- Amneal’s Lanham Act False Advertising claim (Count 3) is **DISMISSED**.
- All claims against Reckitt Benckiser Pharmaceuticals Inc. and Indivior PLC are **DISMISSED**.
- Amneal may file an amended complaint to attempt to cure the deficiencies in its Lanham Act claim within thirty (30) days of the date of this Order.

BY THE COURT:

/s/ **Mitchell S. Goldberg**

MITCHELL S. GOLDBERG, J.